Compare NIE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIE | ARVN |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.4M | 658.2M |
| IPO Year | N/A | 2018 |
| Metric | NIE | ARVN |
|---|---|---|
| Price | $26.88 | $8.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 64.8K | ★ 858.9K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.74 | $6.06 |
| 52 Week High | $27.02 | $14.22 |
| Indicator | NIE | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 37.05 |
| Support Level | $24.71 | $8.72 |
| Resistance Level | $27.02 | $10.18 |
| Average True Range (ATR) | 0.32 | 0.47 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 91.92 | 28.82 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.